Combination of Erlotinib (Tarceva®) and Bevacizumab (Avastin®) as Second-line Treatment in Locally Advanced / Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC) Patients: A Phase II Study
A randomized, placebo-controlled phase III trial of erlotinib versus placebo, demonstrated
that therapy with this tyrosine kinase inhibitor (TKI) prolongs survival after first or
second line therapy in patients with advanced NSCLC. Moreover, the addition of bevacizumab,
a monoclonal antibody against Vascular Endothelial Growth Factor bevacizumab (VEGF), to
systemic chemotherapy, improved both the response rates and the time to tumor progression in
two trials. Early data from phase I/II trials examining the combination of these two
biological agents in pre-treated patients with non-squamous NSCLC, showed no major
pharmacokinetic interactions and promising clinical activity.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Objective responses confirmed by CT or MRI (on 3rd and
No
Sofia Agelaki, MD
Principal Investigator
University Hospital of Crete, Dep of Medical Oncology
Greece: National Organization of Medicines
CT/08.15
NCT00749567
July 2008
September 2010
Name | Location |
---|